行情

SUPN

SUPN

Supernus制药
NASDAQ

实时行情|Nasdaq Last Sale

23.08
-0.10
-0.43%
盘后: 23.08 0 0.00% 16:45 08/07 EDT
开盘
23.21
昨收
23.18
最高
23.22
最低
22.37
成交量
50.64万
成交额
--
52周最高
31.00
52周最低
13.12
市值
12.13亿
市盈率(TTM)
10.67
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测SUPN价格均价为29.00,最高价位33.00,最低价为24.00。

EPS

SUPN 新闻

更多
Will Supernus (SUPN) Beat Estimates Again in Its Next Earnings Report?
Supernus (SUPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks · 07/30 16:10
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q2 Earnings Expected to Decline
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/28 16:33
These 3 Biotech Stocks Are Outperforming Their Peers Here's Why
Investor's Business Daily · 07/07 15:00
5 Things To Know If You Want To Beat The Market
Seeking Alpha - Article · 07/06 11:51
Supernus Sues Apotex for Infringement of Oxtellar XR® Patents
Supernus Pharmaceuticals, Inc. (SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced that earlier today it sued generic drug maker Apotex Inc. and Apotex Corp.
GlobeNewswire · 06/26 22:29
Supernus Pharmaceuticals Inc (SUPN): Hedge Funds Are Snapping Up
Insider Monkey · 06/18 15:19
Supernus' Makeover: A Work In Progress
Seeking Alpha - Article · 06/16 12:23
Piper Sandler Upgrades Supernus Pharmaceuticals to Overweight, Raises Price Target to $31
Piper Sandler analyst David Amsellem upgrades Supernus Pharmaceuticals (NASDAQ:SUPN) from Neutral to Overweight and raises the price target from $25 to $31.
Benzinga · 06/16 09:10

所属板块

制药
+0.19%
制药与医学研究
+0.08%

热门股票

代码
价格
涨跌幅

SUPN 简况

Supernus Pharmaceuticals, Inc.是一家制药公司,专注于开发和销售用于治疗中枢神经系统(CNS)疾病的产品。该公司提供治疗癫痫的产品,包括缓释奥卡西平(Oxtellar XR)和缓释托吡酯(Trokendi XR)。它在精神病学方面开发多个候选产品,用于治疗冲动性攻击(IA)和注意力缺陷多动障碍(ADHD)。其精神病候选产品包括SPN-810(盐酸吗茚酮)和SPN-812(维洛沙秦)。该公司正在开发的SPN-810是一种治疗ADHD患者IA的药品。该公司正在开发的SPN-812用于治疗ADHD。该公司还在开发SPN-809(维洛沙秦),用于治疗抑郁。它通过自己的专业销售团队在美国销售其产品,并与其他制药公司合作,在美国境外授权其产品。
展开

微牛提供Supernus Pharmaceuticals Inc(NASDAQ-SUPN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的SUPN股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易SUPN股票基本功能。